Liberty Mutual Group Asset Management Inc. lessened its stake in shares of Bio-Rad Laboratories (NYSE:BIO) by 22.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,981 shares of the medical research company’s stock after selling 1,125 shares during the period. Liberty Mutual Group Asset Management Inc.’s holdings in Bio-Rad Laboratories were worth $996,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its holdings in Bio-Rad Laboratories by 297.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 560 shares of the medical research company’s stock worth $134,000 after acquiring an additional 419 shares in the last quarter. Eagle Boston Investment Management Inc. bought a new stake in Bio-Rad Laboratories during the first quarter worth about $206,000. Private Advisor Group LLC bought a new stake in Bio-Rad Laboratories during the fourth quarter worth about $248,000. Engineers Gate Manager LP bought a new stake in Bio-Rad Laboratories during the first quarter worth about $280,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Bio-Rad Laboratories by 42.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock worth $278,000 after acquiring an additional 350 shares in the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.
BIO has been the topic of several analyst reports. ValuEngine upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Jefferies Group upped their target price on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Citigroup upped their target price on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. CL King lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a report on Friday, February 16th. Finally, Wells Fargo & Co upped their target price on Bio-Rad Laboratories from $280.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $297.20.
Shares of NYSE BIO opened at $288.91 on Thursday. The company has a market cap of $8.62 billion, a price-to-earnings ratio of 70.47, a price-to-earnings-growth ratio of 3.15 and a beta of 0.95. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.99 and a current ratio of 4.33. Bio-Rad Laboratories has a twelve month low of $208.95 and a twelve month high of $297.59.
Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.22. The firm had revenue of $620.43 million for the quarter, compared to the consensus estimate of $618.89 million. Bio-Rad Laboratories had a return on equity of 3.84% and a net margin of 34.32%. analysts anticipate that Bio-Rad Laboratories will post 6.13 earnings per share for the current fiscal year.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.